Completed
PHASE1
INTERVENTIONAL
NCT01514500
First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This trial is conducted in Europe. The aim of this trial is to assess safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of NNC0195-0092 (somapacitan) compared to placebo in healthy male subjects.
Interventions
Name:
somapacitan
Type:
DRUG
Description:
Administered s.c. (subcutaneously, under the skin)
Name:
placebo (somapacitan)
Type:
DRUG
Description:
Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)
Primary Outcomes
Measure:
Incidence of adverse events (Single Dose)
TimeFrame:
From first administration of trial product and up until day 40
Description:
Measure:
Incidence of adverse events (Multiple Dose)
TimeFrame:
From first administration of trial product and up until day 49
Description:
Trial Information
NCT ID
NCT01514500
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025